Verdiva Bio Limited is a clinical-stage biopharmaceutical company focused on developing next-generation oral and injectable peptide therapies for obesity and cardiometabolic disorders. Verdiva’s most advanced therapy in development is VRB-101, an oral GLP-1 peptide that has demonstrated compelling efficacy potential in a phase 1 study, which also confirmed the viability of once-weekly dosing. The company’s portfolio includes multiple amylin molecules (oral and subcutaneous agonists) and...